2022年度ADC在胰腺癌领域的研究新进展及展望

doi:10.19401/j.cnki.1007-3639.2023.03.006

中国癌症杂志 ›› 2023, Vol. 33 ›› Issue (3): 235-240.doi: 10.19401/j.cnki.1007-3639.2023.03.006

2022年度ADC在胰腺癌领域的研究新进展及展望

曾铖(), 张剑()

复旦大学附属肿瘤医院Ⅰ期临床试验病房，复旦大学上海医学院肿瘤学系，上海 200032

收稿日期:2023-01-30 修回日期:2023-02-23 出版日期:2023-03-30 发布日期:2023-04-17
通信作者: 张剑（ORCID: 0000-0002-7890-4187），博士，主任医师、教授、硕士研究生导师。
作者简介:曾铖（ORCID: 0009-0005-5307-3822），硕士在读。
张剑，复旦大学附属肿瘤医院Ⅰ期临床试验病房行政主任，肿瘤内科主任医师、教授、硕士研究生导师。现任上海市抗癌协会肿瘤药物临床研究专业委员会候任主任委员，长江学术带乳腺联盟主任委员，中国抗癌协会乳腺癌专业委员会常委，中国抗癌协会乳腺癌专业委员会青年委员会副召集人，中国研究型医院协会乳腺专业委员会副主任委员，国家抗肿瘤药物临床应用监测青年委员会副主任委员，乳腺癌整合防治全国专家委员会青年委员会副主任委员，上海市抗癌协会肿瘤药学专业委员会副主任委员，中国临床肿瘤学会肿瘤支持与康复治疗专家委员会常委，中国康复医学会肿瘤康复专业委员会常委，中国临床肿瘤学会青年专家委员会常委，中国临床肿瘤学会乳腺癌专家委员会委员，中国抗癌协会肿瘤临床研究管理学专业委员会委员，国家药品监督管理局药品审评中心首批化药临床兼职审评员。Disease & Research 副主编。以第一作者、共同第一作者和通信作者在SCI收录期刊上发表论文40余篇。

Leading research progress and prospect of antibody-drug conjugate in pancreatic cancer in 2022

ZENG Cheng(), ZHANG Jian()

Phase Ⅰ Clinical Trial Center, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

Received:2023-01-30 Revised:2023-02-23 Published:2023-03-30 Online:2023-04-17
Contact: ZHANG Jian

摘要/Abstract

摘要：

胰腺癌是发病率高且生存率低的一种恶性肿瘤，对于缺乏手术适应证及放化疗效果不好的患者，急需发展新型而高效的治疗手段。近年来，抗体药物偶联物（antibody-drug conjugate，ADC）因其高选择性和抗肿瘤活性等优点而逐渐成为研究热点，在胰腺癌的治疗中已取得一些成果，但是仍需面对诸多挑战。本文对2022年度ADC在胰腺癌领域的研究新进展进行综述。

关键词: 抗体药物偶联物, 胰腺癌, 临床研究

Abstract:

Pancreatic cancer is a type of malignant tumor with high incidence and low survival rate. It is urgent to develop novel and efficient therapeutic means for patients lacking surgical indications and patients with poor effects of radiotherapy and chemotherapy. In recent years, antibody-drug conjugate (ADC) has become hot because of their high selectivity and anti-tumor activity. ADC has achieved some results in the treatment of pancreatic cancer, but still face many challenges. This article provided a brief review of the latest developments of ADC in pancreatic cancer in 2022.

Key words: Antibody-drug conjugate, Pancreatic cancer, Clinical research

中图分类号:

R735.9

曾铖, 张剑. 2022年度ADC在胰腺癌领域的研究新进展及展望[J]. 中国癌症杂志, 2023, 33(3): 235-240.

ZENG Cheng, ZHANG Jian. Leading research progress and prospect of antibody-drug conjugate in pancreatic cancer in 2022[J]. China Oncology, 2023, 33(3): 235-240.

参考文献 21

[1]	CABASAG C J, FERLAY J, LAVERSANNE M, et al. Pancreatic cancer: an increasing global public health concern[J]. Gut, 2022, 71(8): 1686-1687.
[2]	HOSEIN A N, BREKKEN R A, MAITRA A. Pancreatic cancer stroma: an update on therapeutic targeting strategies[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(8): 487-505. doi: 10.1038/s41575-020-0300-1 pmid: 32393771
[3]	CHAU C H, STEEG P S, FIGG W D. Antibody-drug conjugates for cancer[J]. Lancet, 2019, 394(10200): 793-804. doi: S0140-6736(19)31774-X pmid: 31478503
[4]	QI C S, GONG J F, LI J, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results[J]. Nat Med, 2022, 28(6): 1189-1198. doi: 10.1038/s41591-022-01800-8 pmid: 35534566
[5]	KYUNO D, TAKASAWA A, TAKASAWA K, et al. Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials[J]. Tissue Barriers, 2022, 10(1): 1967080.
[6]	XU R H, WEI X L, ZHANG D S, et al. A phase 1a dose-escalation, multicenter trial of anti-claudin 18.2 antibody drug conjugate CMG901 in patients with resistant/refractory solid tumors[J]. J Clin Oncol, 2023, 41(4_suppl): 352.
[7]	CAZES A, BETANCOURT O, ESPARZA E, et al. A MET targeting antibody-drug conjugate overcomes gemcitabine resistance in pancreatic cancer[J]. Clin Cancer Res, 2021, 27(7): 2100-2110. doi: 10.1158/1078-0432.CCR-20-3210 pmid: 33451980
[8]	JIN Y B, ZHANG Z H, ZOU S Y, et al. A novel c-MET-targeting antibody-drug conjugate for pancreatic cancer[J]. Front Oncol, 2021, 11: 634881.
[9]	GYMNOPOULOS M, BETANCOURT O, BLOT V, et al. TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors[J]. Mol Oncol, 2020, 14(1): 54-68. doi: 10.1002/1878-0261.12600 pmid: 31736230
[10]	NAKANO T. Systemic treatment of malignant pleural mesothelioma[J]. Gan To Kagaku Ryoho, 2017, 44(13): 2041-2047.
[11]	HASSAN R, BLUMENSCHEIN G R Jr, MOORE K N, et al. First-in-human, multicenter, phase I dose-escalation and expansion study of anti-mesothelin antibody-drug conjugate anetumab ravtansine in advanced or metastatic solid tumors[J]. J Clin Oncol, 2020, 38(16): 1824-1835. doi: 10.1200/JCO.19.02085 pmid: 32213105
[12]	SPILIOPOULOU P, KASI A, ABUSHAHIN L I, et al. Phase Ib study of anetumab ravtansive in combination with immunotherapy or immunotherapy plus chemotherapy in mesothelin-enriched advanced pancreatic adenocarcinoma: NCI10208[J]. J Clin Oncol, 2022, 40(16_suppl): 4136. doi: 10.1200/JCO.2022.40.16_suppl.4136
[13]	CUBAS R, ZHANG S, LI M, et al. Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway[J]. Mol Cancer, 2010, 9: 253. doi: 10.1186/1476-4598-9-253 pmid: 20858281
[14]	CARDILLO T M, GOVINDAN S V, SHARKEY R M, et al. Sacituzumab govitecan (IMMU-132), an anti-trop-2/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers[J]. Bioconjug Chem, 2015, 26(5): 919-931. doi: 10.1021/acs.bioconjchem.5b00223
[15]	BARDIA A, MESSERSMITH W A, KIO E A, et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase Ⅰ/Ⅱ IMMU-132-01 basket trial[J]. Ann Oncol, 2021, 32(6): 746-756. doi: 10.1016/j.annonc.2021.03.005
[16]	YANG M C, SHIA C S, LI W F, et al. Preclinical studies of OBI-999: a novel globo H-targeting antibody-drug conjugate[J]. Mol Cancer Ther, 2021, 20(6): 1121-1132. doi: 10.1158/1535-7163.MCT-20-0763
[17]	HAN Z W, LYV Z W, CUI B, et al. The old CEACAMs find their new role in tumor immunotherapy[J]. Invest New Drugs, 2020, 38(6): 1888-1898. doi: 10.1007/s10637-020-00955-w
[18]	DERY K J, GAUR S, GENCHEVA M, et al. Mechanistic control of carcinoembryonic antigen-related cell adhesion molecule-1 (CEACAM1) splice isoforms by the heterogeneous nuclear ribonuclear proteins hnRNP L, hnRNP A1, and hnRNP M[J]. J Biol Chem, 2011, 286(18): 16039-16051. doi: 10.1074/jbc.M110.204057 pmid: 21398516
[19]	TIAN B M, WONG W Y, UGER M D, et al. Development and characterization of a camelid single domain antibody-urease conjugate that targets vascular endothelial growth factor receptor 2[J]. Front Immunol, 2017, 8: 956. doi: 10.3389/fimmu.2017.00956 pmid: 28871252
[20]	TIAN B, WONG W Y, HEGMANN E, et al. Production and characterization of a camelid single domain antibody-urease enzyme conjugate for the treatment of cancer[J]. Bioconjugate Chem, 2015, 26(6): 1144-1155. doi: 10.1021/acs.bioconjchem.5b00237 pmid: 25938892
[21]	SINGH C S B, EYFORD B A, ABRAHAM T, et al. Discovery of a highly conserved peptide in the iron transporter melanotransferrin that traverses an intact blood brain barrier and localizes in neural cells[J]. Front Neurosci, 2021, 15: 596976.

2022年度ADC在胰腺癌领域的研究新进展及展望

Leading research progress and prospect of antibody-drug conjugate in pancreatic cancer in 2022

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 21

相关文章 15

编辑推荐

Metrics

本文评价

[1]	田熙, 徐文浩, 朱殊璇, 艾合太木江·安外尔, 宿佳琦, 叶世琪, 瞿元元, 施国海, 张海梁, 叶定伟. 2022年度肾细胞癌基础研究及临床诊疗新进展[J]. 中国癌症杂志, 2023, 33(3): 191-200.
[2]	郑盛锋, 朱一平, 叶定伟. 2022年度膀胱癌基础研究及临床诊疗新进展[J]. 中国癌症杂志, 2023, 33(3): 201-209.
[3]	潘剑, 朱耀, 戴波, 叶定伟. 2022年度前列腺癌基础研究及临床诊疗新进展[J]. 中国癌症杂志, 2023, 33(3): 210-217.
[4]	符庆胜, 金雷, 张旭东, 徐荧晨, 朱春富, 秦锡虎, 吴宝强. tRF-Pro-CGG对小鼠胰腺癌细胞生物学行为的影响及其分子机制[J]. 中国癌症杂志, 2023, 33(3): 241-249.
[5]	张会强, 江泽飞. 2022年改变晚期乳腺癌临床实践的重要研究[J]. 中国癌症杂志, 2023, 33(2): 110-116.
[6]	王旭, 程合, 刘辰, 虞先濬. 2022年度胰腺癌研究及诊疗新进展[J]. 中国癌症杂志, 2023, 33(1): 1-13.
[7]	庄晗, 凌池芳, 王佳舟, 韩序, 姜睿, 胡伟刚. 局部晚期胰腺癌75 Gy同步加量放射治疗的剂量可行性研究[J]. 中国癌症杂志, 2023, 33(1): 54-60.
[8]	李语婕, 陈颢. 靶向TROP2在胰腺癌治疗中的潜力[J]. 中国癌症杂志, 2022, 32(3): 268-273.
[9]	吴梦吟, 吴春晓, 庞怡, 王春芳, 顾凯, 龚杨明, 鲍萍萍, 施亮, 窦剑明, 向詠梅, 施燕. 2016年上海市胰腺癌发病和死亡情况与2002—2016年流行趋势分析[J]. 中国癌症杂志, 2022, 32(2): 97-105.
[10]	罗国培, 虞先濬. 胰腺癌精准治疗：从小众走向主流[J]. 中国癌症杂志, 2022, 32(10): 960-970.
[11]	朱鑫哲, 李浩, 徐华祥, 罗国培, 虞先濬. 2021年胰腺癌研究及诊疗新进展[J]. 中国癌症杂志, 2022, 32(1): 1-12.
[12]	杨士鹏, 刘颖, 王馨悦, 杨洋, 全吉淑, 林贞花 . PKLR在胰腺癌中的表达水平及临床病理学意义[J]. 中国癌症杂志, 2021, 31(8): 704-713.
[13]	朱逸晖, 李　婷, 胡夕春. Trastuzumab deruxtecan的临床研究进展及展望——HER2耐药患者的新希望[J]. 中国癌症杂志, 2021, 31(8): 754-761.
[14]	唐　榕, 施　思, 张　波, 徐　近, 王　巍, 虞先濬. 2020年胰腺癌研究及诊疗新进展[J]. 中国癌症杂志, 2021, 31(1): 1-10.
[15]	张晓萌 , 麻宁一 , 祝鸿程 , 艾沓杉 , 任志刚 . 胰腺癌术后辅助性放化疗的效果及预后因素分析[J]. 中国癌症杂志, 2020, 30(7): 519-524.